BioSpace38m
Nasdaq Neophytes Acelyrin, Alumis Merge to Tackle Immune-Mediated Diseases
Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...
BioSpace1h
Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
BioSpace1h
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
BioSpace21h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
BioSpace22h
BMS’ Cobenfy Sales Begin, With Launch Full Speed Ahead
Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...
BioSpace23h
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...
BioSpace23h
BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success
Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...